Legis Daily

Ending the Diagnostic Odyssey Act of 2021

USA117th CongressS-2022| Senate 
| Updated: 6/10/2021
Susan M. Collins

Susan M. Collins

Republican Senator

Maine

Cosponsors (3)
Tina Smith (Democratic)Robert Menendez (Democratic)Mark Kelly (Democratic)

Finance Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Ending the Diagnostic Odyssey Act of 2021 This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals. Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease. The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-3116
Ending the Diagnostic Odyssey Act of 2019
Jun 10, 2021
Introduced in Senate
Jun 10, 2021
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047)
  • Bill from Previous Congress

    S 116-3116
    Ending the Diagnostic Odyssey Act of 2019


  • June 10, 2021
    Introduced in Senate


  • June 10, 2021
    Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047)

Health

Adoption and foster careCell biology and embryologyChild healthEmergency medical services and trauma careGeneticsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth programs administration and fundingHealth technology, devices, suppliesHospital careMedicaidMedical tests and diagnostic methodsState and local government operations

Ending the Diagnostic Odyssey Act of 2021

USA117th CongressS-2022| Senate 
| Updated: 6/10/2021
Ending the Diagnostic Odyssey Act of 2021 This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals. Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease. The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline

Bill from Previous Congress

S 116-3116
Ending the Diagnostic Odyssey Act of 2019
Jun 10, 2021
Introduced in Senate
Jun 10, 2021
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047)
  • Bill from Previous Congress

    S 116-3116
    Ending the Diagnostic Odyssey Act of 2019


  • June 10, 2021
    Introduced in Senate


  • June 10, 2021
    Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S4046-4047)
Susan M. Collins

Susan M. Collins

Republican Senator

Maine

Cosponsors (3)
Tina Smith (Democratic)Robert Menendez (Democratic)Mark Kelly (Democratic)

Finance Committee

Health

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Adoption and foster careCell biology and embryologyChild healthEmergency medical services and trauma careGeneticsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth programs administration and fundingHealth technology, devices, suppliesHospital careMedicaidMedical tests and diagnostic methodsState and local government operations